Amphastar Pharmaceuticals Q4 Earnings Call Highlights

Several established products saw sizable declines. Peters said glucagon sales fell 45% to $14.1 million , citing increased competition and a market shift toward ready-to-use products such as BAQSIMI. Epinephrine sales declined 9% to $17.1 million due to increased competition for the company’s epinephrine multi-dose vial products, partially offset by higher unit volumes for epinephrine pre-filled syringes amid supplier shortages during the quarter.Newer products also began contributing, including $4.4 millio ...